Two doses of the Johnson & Johnson (J&J) Covid-19 vaccine cut the risk of hospitalisation by up to 85 per cent, according to a South African study conducted when the Omicron coronavirus variant was dominant.
The findings of the real-world study, made public on Thursday and not yet peer-reviewed, provide a significant fillip to the J&J shot, widely used in South Africa and elsewhere.
The world is grappling with an explosion in coronavirus cases caused by the variant, which was first identified late last month in southern Africa.
JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Trust aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly.
